By Fineline Cube 
Sino-US biotech Sirius Therapeutics has entered into a partnership with Swiss–American biotech CRISPR Therapeutics (NASDAQ: CRSP) to develop and commercialize SRSD107, a Factor XI (FXI)-targeted Factor siRNA therapy for the treatment of thrombosis and thromboembolic diseases.
Agreement Details
Under the agreement, CRISPR Therapeutics will provide Sirius Therapeutics with an upfront payment of USD 25 million in cash and USD 70 million in equity. The two companies will share development costs and profits equally. CRISPR Therapeutics will lead U.S. commercialization efforts, while Sirius retains exclusive rights in Greater China.
SRSD107 Development
By targeting FXI, SRSD107 aims to reduce thrombotic events while minimizing the risk of bleeding, offering a differentiated approach compared to Factor Xa inhibitors. The drug is being developed to treat patients with atrial fibrillation, venous thromboembolism (VTE), cancer-associated thrombosis, chronic Coronary Artery Disease (CAD), chronic Peripheral Vascular Disease (PVD), end-stage renal disease requiring hemodialysis, and patients undergoing major orthopedic surgery, where bleeding risk limits existing therapies.
Clinical Trials
SRSD107 has completed two Phase I clinical trials, with results demonstrating its good safety and tolerability. A Phase II study is currently being initiated to assess the drug’s safety and efficacy for the prevention of VTE in patients undergoing total knee arthroplasty.-Fineline Info & Tech